Rocket Pharmaceuticals Inc (RCKT): Company Cash Volume

Corporate emblem and logo of Rocket Pharmaceuticals, Inc. (RCKT)

Rocket Pharmaceuticals is expanding its R&D through alliances with universities, although full capacity utilization and line modernization are constraining the pace. The cash balance history on the GURU.Markets chart resolves this dispute, where 0.27 reflects the metric's baseline. Stable demand for gene therapy supports the business, although geopolitics complicates logistics and patent protection.

Rocket Corp - RCKT Company Cash Volume (period 07/04/2022 - 11/21/2026)

Analytical breakdowns and data insights for company Rocket Pharmaceuticals, Inc. (RCKT)

- stock quotes and analyst forecast:
- cash position and cash flow details:
Fundamental company analysis:Rocket Corp
Brand item of rocketpharma.com

Rocket Pharmaceuticals is developing costly gene therapy technologies that require colossal capital expenditures. The current change in cash on hand of 0.27 reflects the daily balance of liquid assets, allowing for an assessment of the price's financial stability. This indicator captures the actual volume of cash reserves necessary to cover operating expenses. For Rocket Pharmaceuticals (RCKT), this reserve is critically important to avoid resource depletion in the event of FDA approval delays or rising production costs.

Analysis of competing companies

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume